EGFR and head and neck squamous cell carcinoma: C‐Myc belongs to the mitogenic signaling pathway downstream of EGFR and may contribute to the limited clinical effectiveness of EGFR inhibitors despite frequent EGFR‐overexpression in HNSCC [36].